Bayer’s outlook following its recent acquisition (CNBC)
Private equity firms bid on Stada (In Vivo)
Brian McGee, Principal at Novasecta, provided his perspective on the recent bids by private equity firms Cinven and Advent on German generics firm Stada in an article in Scrip. Brian stated that “Cinven have a reputation for value creation through industry consolidation, where an initial investment acts as a platform to which other complementary businesses […]
Keeping it in the family pays dividends (PME)
Novasecta, was recently quoted extensively in an article in Pharmaceutical Market Europe discussing the advantages of being a family- or foundation-controlled pharmaceutical company. Historically a strong focus area, Novasecta has seen first-hand how family- aednd foundation-controlled companies can leverage their unique position by focusing on long-term strategies that often translate into success. The article can be read here, […]
Sanofi CEO hopes for positive results (Scrip)
John Rountree, Managing Partner at Novaescta, was asked by Scrip to comment on Sanofi’s recently reported on-target Q4 results and their outlook for the future. While these results likely reassured investors and analysts that their strategic plan is on track, the real test for Sanofi is yet to come, with multiple critical catalysts expected in […]
GSK’s prospects (CNBC)
